Literature DB >> 16207572

Management of ascites in cirrhosis.

Bimaljit Singh Sandhu1, Arun J Sanyal.   

Abstract

Onset of ascites in cirrhosis of the liver is associated with worsened quality of life, increased risk of spontaneous bacterial peritonitis, and renal failure. Portal hypertension produces splanchnic vasodilation that triggers the cascade of events leading to release of Na retentive vasoconstrictor hormones. Management of ascites caused by cirrhosis is based on improving the Na excretion with diuretics and Na restriction in diet. Refractory ascites and hepatorenal syndrome are the complications of ascites that carry a very high mortality. Large volume paracentesis and transjugular intrahepatic porto-systemic shunts are useful in managing patients with refractory ascites. Liver transplant is the only way to improve survival in ascites caused by cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207572     DOI: 10.1016/j.cld.2005.07.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

1.  Clinical value of urinary retinol-binding protein in ascites due to cirrhosis.

Authors:  Yujing Xia; Jingjing Li; Sainan Li; Tong Liu; Yuqing Zhou; Qin Yin; Jianrong Wang; Wenxia Lu; Rong Zhang; Yuanyuan Zheng; Fan Wang; Jie Lu; Kan Chen; Weiqi Dai; Yingqun Zhou; Chuanyong Guo
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

2.  Diagnosis and treatment of hepatic sarcoidosis.

Authors:  Uma S Ayyala; Maria L Padilla
Journal:  Curr Treat Options Gastroenterol       Date:  2006

3.  Qi Sui Zhu Shui Plaster Inhibits AQP1 and MAPK Signaling Reduces Liver Damage Induced by Cirrhotic Ascites.

Authors:  Rong Zhen Zhang; Yin Liu; Min Li; Yong Lin Huang; Zhen Heng Song
Journal:  J Healthc Eng       Date:  2022-03-30       Impact factor: 2.682

4.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.

Authors:  M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 9.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.